Skip to content
Study details
Enrolling now

AMT-116 Trial for Advanced Cancer

Multitude Therapeutics Inc.
NCT IDNCT05725291ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

80

Study length

about 3.4 years

Ages

18+

Locations

2 sites in CO, TX

What this study is about

This trial is testing a new medication called AMT-116 to see if it's safe and effective in people with advanced solid tumors. The goal of this phase 1 trial is to determine the highest dose that can be tolerated, as well as how the drug affects patients.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take AMT-116

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Maximum Tolerated Dose (MTD), Recommended Phase 2 Dose (RP2D), Type, incidence and severity of Adverse Events

Secondary: Area under the curve (AUC), Disease Control Rate (DCR) according to the RECIST v1.1, Overall Response Rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Progression-free Survival (PFS), Terminal half-life (t[1/2]), Time to maximum concentration (Tmax)

Body systems

Oncology